GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-inflammatory diseases. Its stock price is highly volatile and reflects binary events—the success or failure of clinical trials and FDA decisions.
Share prices of companies in the market segment - Pharma eyes
Aldeyra Therapeutics (ALDX) is a biotechnology company developing novel drugs for the treatment of immune-mediated ocular diseases and systemic conditions. We classify the company in the Pharmaceuticals/Eye Diseases sector. The chart below shows the overall performance of the ophthalmic biotechnology sector.
Broad Market Index - GURU.Markets
Aldeyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-inflammatory diseases, particularly eye diseases. As a component of the GURU.Markets index, it represents the ophthalmology sector. The chart below represents the entire market. See how Aldeyra shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ALDX - Daily change in the company's share price Aldeyra Therapeutics
The volatility of Aldeyra Therapeutics, a biopharmaceutical company, reflects risks associated with regulatory decisions. Change_co measures sensitivity to FDA news regarding its eye medications. This parameter is important for formulas on System.GURU.Markets that analyze binary events in biotech.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Aldeyra Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ALDX, a company focused on eye disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Aldeyra is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Aldeyra's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aldeyra Therapeutics
Aldeyra Therapeutics' year-to-date performance is a story about developing drugs for the treatment of inflammatory eye diseases. Its 12-month market cap is crucially dependent on FDA decisions. Approval of its dry eye drops is a fundamental event that could transform the company into a commercial company, while a rejection would be a serious blow.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Aldeyra Therapeutics, Inc. is a biopharmaceutical company developing a new class of drugs for the treatment of immune diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aldeyra Therapeutics is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aldeyra Therapeutics
The performance of Aldeyra, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news related to FDA approvals for its eye disease drugs, a key factor in determining its value.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Ophthalmology biotechnology is a knowledge-intensive field, where company valuations depend on clinical trial results and regulatory decisions. The dynamics of this sector, visible in the graph, reflect its event-driven nature. In this context, developers like Aldeyra Therapeutics are promoting their drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aldeyra Therapeutics develops drugs for the treatment of ocular and systemic diseases. Like many biotechs, its shares are driven by news of clinical trials and regulatory decisions. Their performance is completely disconnected from the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aldeyra Therapeutics
Aldeyra Therapeutics, a biotech company focused on treating inflammatory eye diseases, exhibits high volatility. Its weekly stock price is a direct response to FDA decisions and clinical trial data, where a single piece of news can cause a sharp rise or fall in price.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Biotech companies developing eye treatments, like Aldeyra, are riding the wave of industry-wide news. The chart below illustrates this industry sentiment. It allows one to assess how promising the market perceives Aldeyra's approach compared to other companies' developments in ophthalmology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aldeyra Therapeutics is a biotech company with a portfolio of drugs for the treatment of inflammatory diseases, primarily eye diseases. Its shares are driven by news of FDA decisions and trial data. The chart shows how their performance is unrelated to overall market trends.
Market capitalization of the company, segment and market as a whole
ALDX - Market capitalization of the company Aldeyra Therapeutics
Aldeyra Therapeutics' market capitalization reflects investors' bets on its novel chemistry for treating inflammatory diseases. The chart shows how the market values its platform, which targets reactive aldehydes. Its high volatility reflects both setbacks in some clinical programs and hopes for success in others, such as eye disease treatment.
ALDX - Share of the company's market capitalization Aldeyra Therapeutics within the market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company focused on the treatment of immune-mediated eye diseases. Within its narrow segment, its market capitalization reflects the potential of its innovative drugs. The dynamics of this metric reflect the market's sensitive reaction to regulatory decisions and clinical trial data, which shape the company's future.
Market capitalization of the market segment - Pharma eyes
This chart shows the total value of the entire biotech sector focused on eye diseases. For Aldeyra Therapeutics, which develops drugs for inflammatory diseases, this line demonstrates the scale of the market. The rising chart reflects the enormous need for new treatments that could improve the vision and quality of life for millions of people.
Market capitalization of all companies included in a broad market index - GURU.Markets
Aldeyra Therapeutics develops drugs to treat inflammatory diseases, primarily eye diseases. Its market capitalization is a measure of its research portfolio. Overall, this represents the market share that is willing to devote to finding solutions to improve vision and quality of life.
Book value capitalization of the company, segment and market as a whole
ALDX - Book value capitalization of the company Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company focused on treating inflammatory diseases. Its book value is its research capital, consisting of funds needed to conduct clinical trials. How has this research budget evolved? The chart below shows this history.
ALDX - Share of the company's book capitalization Aldeyra Therapeutics within the market segment - Pharma eyes
Aldeyra Therapeutics focuses on aldehyde-induced diseases. Its scientific platform requires a modern laboratory for developing and testing new small molecules for the treatment of ocular and systemic diseases. The chart shows the company's share of the physical R&D infrastructure for this innovative field.
Market segment balance sheet capitalization - Pharma eyes
Aldeyra Therapeutics, a biopharmaceutical company, has a relatively lightweight model. It focuses on developing its own drugs, often outsourcing manufacturing. The BCap_Seg chart for the biotech sector serves as a backdrop, showing the varying levels of capital intensity.
Book value of all companies included in the broad market index - GURU.Markets
Aldeyra Therapeutics' capital comes not from its factories, but from its scientific platform for developing aldehyde-targeted drugs for the treatment of ocular and systemic inflammatory diseases. Its book value reflects its investment in R&D. The chart shows how this knowledge-intensive asset is valued within the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aldeyra Therapeutics
Aldeyra's balance sheet represents its R&D capital. Its entire market value represents a premium for its scientific platform and pipeline of developments for treating ocular and systemic diseases. The graph represents investors' aggregate assessment of the likelihood of success for its clinical programs.
Market to book capitalization ratio in a market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company developing drugs for the treatment of inflammatory eye diseases. Its valuation on this chart is highly dependent on regulatory decisions and clinical trial results, creating a high degree of uncertainty.
Market to book capitalization ratio for the market as a whole
Aldeyra Therapeutics is a biotech company developing drugs for the treatment of inflammatory eye diseases. Its market value depends on progress in clinical trials and regulatory approval. This chart shows how expectations create a valuation independent of its current tangible assets.
Debts of the company, segment and market as a whole
ALDX - Company debts Aldeyra Therapeutics
Aldeyra Therapeutics, a biopharmaceutical company developing drugs to treat inflammatory eye diseases, uses capital to fund its clinical programs. This chart shows how the company manages its resources to bring its innovative molecules to market, which requires significant and risky investments.
Market segment debts - Pharma eyes
Aldeyra Therapeutics is a biotech company developing drugs for the treatment of inflammatory eye diseases and systemic illnesses. Having an approved product changes the financial picture, but R&D still requires expenses. This chart shows how the company balances commercialization costs with funding for future development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aldeyra Therapeutics
Aldeyra Therapeutics is a pharmaceutical company focused on treating ocular and systemic inflammatory diseases. This chart shows how it funds its clinical trials. It reflects the high level of financial risk: the company spends significant amounts of investor money in the hopes of developing and bringing a marketable drug to market.
Market segment debt to market segment book capitalization - Pharma eyes
Aldeyra Therapeutics develops drugs to treat inflammatory diseases, primarily eye diseases. Ophthalmology is a specialized but large market. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how Aldeyra finances its clinical research and drug launches.
Debt to book value of all companies in the market
Aldeyra Therapeutics, which develops drugs to treat eye and systemic immune diseases, conducts expensive clinical trials. This chart, which reflects the market's overall debt load, provides important context. It helps understand how the company finances its innovation portfolio and how its debt policy compares to other biotech players.
P/E of the company, segment and market as a whole
P/E - Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company developing new treatments for immune-mediated diseases, with a focus on eye diseases. This chart shows how the market values its research and development. This value is based on clinical trial success and the commercial potential of its drugs.
P/E of the market segment - Pharma eyes
Aldeyra Therapeutics develops drugs to treat eye diseases. This chart shows the average valuation for the biotech sector. It serves as a backdrop for Aldeyra's valuation: investors look not at its profits, but at the potential of its developments in this large and competitive therapeutic area.
P/E of the market as a whole
Aldeyra Therapeutics is a biopharmaceutical company developing new treatments for immune-mediated diseases, with a particular focus on eye diseases. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether ALDX's valuation is based on the potential of its eye treatments or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company developing drugs to treat immune-mediated ocular and systemic diseases. This chart shows market expectations for its innovative approaches and the commercial potential of its pipeline if clinical trials are successful.
%20P%2FE%20Aldeyra%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aldeyra-Therapeutics&v=1772640838068 "Chart of the company's future (projected) P/E Aldeyra Therapeutics")
Future (projected) P/E of the market segment - Pharma eyes
Aldeyra Therapeutics develops drugs for the treatment of immune-mediated diseases, with a particular focus on eye diseases. The data here reflects the analysts' collective bets on the success of its clinical programs. It is a barometer of expectations for its innovative molecules to gain approval and find their way to patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772640838147 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Aldeyra Therapeutics develops drugs to treat inflammatory eye diseases. This is a highly specialized area with high potential. This chart of overall market expectations shows that investors can value companies with a clear focus and late-stage products, even if the overall market is volatile.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640838165 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aldeyra Therapeutics
Aldeyra Therapeutics develops drugs to treat immune-mediated diseases, with a particular focus on ophthalmology. This chart illustrates the financial side of pharmaceutical innovation. It reflects the costs of clinical trials, which, if successful, could lead to the development of a new class of eye medications.
Profit of companies in the market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company specializing in the treatment of immune-mediated diseases, including eye diseases. Its financial history is a history of investment in research. The clinical success of its drugs is key to future profitability and reflects advances in the treatment of complex diseases.
Overall market profit
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-mediated eye diseases and systemic illnesses. Its success depends on the approval of its drugs. The overall economic situation, reflected in this chart, influences the investment climate. For companies awaiting regulatory approval, access to capital during this period is vital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company developing new drugs for the treatment of immune-mediated diseases, with a focus on ophthalmology. This chart reflects analysts' speculative expectations. The forecast depends on regulatory decisions regarding their drug candidates and the success of their commercial launches.
%20profit%20of%20the%20company%20Aldeyra%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aldeyra-Therapeutics&v=1772640838327 "Graph of future (projected) profit of the company Aldeyra Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-mediated diseases, primarily eye diseases. The profitability forecasts for this sector, shown in the graph, reflect general trends in ophthalmology. This chart helps assess the potential for Aldeyra's innovative drugs to find their niche in this competitive market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772640838367 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Aldeyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases. Its success depends on regulatory approval and product commercialization. Raising capital for these projects becomes easier in a strong market, which often accompanies a positive outlook, as presented here.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640838420 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company developing novel treatments for immune-mediated eye diseases and systemic illnesses. Its revenue may be limited. This chart shows how investors view its scientific pipeline and the commercial potential of its late-stage drugs.
P/S market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-mediated diseases, with a particular focus on eye diseases. This metric reflects the average revenue estimate for the sector and helps assess the market's confidence in the success of clinical trials and the commercial potential of Aldeyra's developments.
P/S of the market as a whole
Aldeyra Therapeutics is a biopharmaceutical company specializing in the treatment of diseases caused by elevated aldehyde levels. The company focuses on ophthalmology and systemic immune diseases. This chart shows how the market values companies based on current revenues, providing a backdrop for analyzing the biotech sector.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aldeyra Therapeutics
Aldeyra Therapeutics develops drugs to treat immune-mediated diseases, particularly eye diseases. This chart shows investor estimates of its potential future revenue. This estimate is contingent on the success of its clinical programs and regulatory approval of its innovative therapies.
%20P%2FS%20Aldeyra%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aldeyra-Therapeutics&v=1772640838605 "The graph of the company's future (projected) P/S Aldeyra Therapeutics")
Future (projected) P/S of the market segment - Pharma eyes
Aldeyra Therapeutics develops new treatments for immune-mediated diseases, particularly eye diseases. This chart compares market expectations for its future revenue with other ophthalmology pharmaceutical companies. This valuation reflects investor confidence in its scientific platform and the commercial potential of its drug candidates.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772640838804 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Aldeyra Therapeutics is a biotech company developing drugs to treat inflammatory diseases, primarily in ophthalmology. Its success depends on clinical trial results and regulatory approval. This overall revenue expectation schedule is irrelevant for Aldeyra, whose value is created in laboratories and clinics, not in the general market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640838847 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aldeyra Therapeutics
This chart shows the revenue of Aldeyra Therapeutics, a biopharmaceutical company focused on treating inflammatory diseases, primarily eye diseases. The company's revenue can be irregular and comes from partnerships or limited sales of approved drugs. The dynamics reflect the complex path from clinical trials to full commercialization of a product.
Sales of companies in the market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company developing new treatments for immune-mediated diseases. Its primary focus is on eye diseases such as dry eye and allergic conjunctivitis. This chart shows revenue in the ophthalmic pharmaceuticals sector. It reflects the large and growing market for eye treatments, a niche in which Aldeyra is seeking to carve out its niche.
Overall market sales
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-mediated eye diseases. Demand for its potential drugs is driven by medical needs. However, the overall economic growth reflected in this chart ensures the financial stability of healthcare systems and insurance companies that will cover the costs of treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aldeyra Therapeutics
Aldeyra Therapeutics is a biopharmaceutical company developing drugs for the treatment of immune-mediated diseases. This projected revenue chart reflects expectations for the commercial success of its products. The dynamics of this figure are linked to forecasts for the approval and launch of its drugs, particularly those for eye diseases, and their acceptance by the medical community.
%20sales%20of%20the%20company%20Aldeyra%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aldeyra-Therapeutics&v=1772640839118 "Schedule of future (projected) sales of the company Aldeyra Therapeutics")
Future (projected) sales of companies in the market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company developing new treatments for immune-mediated diseases. Their approach involves capturing and neutralizing aldehydes, which cause inflammation. This chart shows projected revenue for the entire ophthalmic pharmaceutical sector, reflecting the search for new approaches to treating inflammatory diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772640839170 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Aldeyra Therapeutics is a biotech company focused on treating immune-mediated diseases, primarily eye diseases. Its success depends on regulatory approval and physician acceptance of its drugs. A stable economic environment ensures the sustainability of healthcare systems, which can cover the costs of such innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640839223 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aldeyra Therapeutics
Aldeyra Therapeutics is a biopharmaceutical company focused on treating inflammation-related diseases. Some of its programs are in late stages. The profitability chart shows a transition period: the company still incurs significant R&D expenses but is already beginning to invest in marketing in anticipation of a potential product launch.
Market segment marginality - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company developing new treatments for immune-mediated diseases, particularly eye diseases. This chart compares its operating efficiency to other biotech companies. Its current competitive advantage may be due to advance payments from drug development partners.
Market marginality as a whole
Aldeyra Therapeutics is a biotech company specializing in the treatment of inflammatory diseases. Its value is determined not by the economy, but by progress in clinical trials. Successful development of drugs for the treatment of eye diseases or systemic inflammation could create enormous value for shareholders.
Employees in the company, segment and market as a whole
Number of employees in the company Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company developing drugs to treat immune diseases, primarily eye diseases. This graph shows a team that has experienced both ups and downs. The staff dynamics can reflect both progress in some clinical programs and setbacks in others, which is typical for biotech.
Share of the company's employees Aldeyra Therapeutics within the market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-mediated diseases, particularly eye diseases. Its team consists of a small group of scientists and clinicians. This chart reflects its current status: its small staff means the company is fully focused on clinical trials.
Number of employees in the market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company focused on treating aldehyde-related diseases, primarily in ophthalmology. This chart illustrates the ups and downs of the biotech industry. Employee dynamics can fluctuate dramatically depending on regulatory decisions (FDA) to approve or reject new drugs, a key factor for small pharmaceutical companies.
Number of employees in the market as a whole
Aldeyra Therapeutics is a biopharmaceutical company focused on treating aldehyde-related diseases, particularly eye diseases. Its workforce is growing as its drugs advance through clinical trials. This total employment chart shows that in the biotech world, job creation is a direct result of scientific investment and progress in drug development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics is a biopharmaceutical company developing drugs to treat immune-mediated eye diseases and systemic illnesses. This chart demonstrates the company's enormous per-employee value. This is typical for biotech, where market valuation is based on the potential of the company's pipeline, not on current revenue or physical assets.
%20of%20the%20company%20Aldeyra%20Therapeutics%20(ALDX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aldeyra-Therapeutics-ALDX&v=1772640839493 "Chart of market capitalization per employee (in thousands of dollars) of the company Aldeyra Therapeutics (ALDX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company specializing in the treatment of inflammatory diseases. This metric reflects investor expectations for their product portfolio. The high cost per employee suggests that the market sees significant commercial potential in their developments, which target large and underserved markets.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772640839544 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Aldeyra Therapeutics is a biotech company developing drugs to treat immune diseases. This metric illustrates a business at the cutting edge of science. Its market capitalization is based on the potential of its scientific platform. Even a small team of scientists can be worth hundreds of millions if their technology is recognized as promising.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640839624 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics is a biotech company developing drugs to treat immune diseases, primarily eye diseases. They are in the clinical or early commercial stages. This graph shows their path to profitability. Negative numbers represent R&D costs. Positive numbers represent early returns on their niche drugs.
%20Chart%20Aldeyra%20Therapeutics%20(ALDX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aldeyra-Therapeutics-ALDX&v=1772640839670 "Company Profit Per Employee (in thousands of dollars) Chart Aldeyra Therapeutics (ALDX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company specializing in the treatment of inflammatory diseases, particularly eye diseases. The company has no profit, only R&D expenses. This metric reflects capital burn per employee, which investors compare to industry standards to assess discipline in R&D spending.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772640839690 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Aldeyra Therapeutics is a biotech company developing drugs for the treatment of immune diseases, primarily ocular. These drugs are in the late clinical stage. This chart shows the balance between increasing R&D costs (late-stage trials) and preparation for commercialization. This represents the cost of bringing an innovative ophthalmic drug to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640839713 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics is a biotech company developing drugs for the treatment of inflammatory eye diseases and systemic illnesses. This chart shows the company's progress toward commercialization. Revenue per employee growth will reflect success in securing approvals and launching its products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aldeyra-Therapeutics-ALDX&v=1772640839789 "Sales chart per company employee Aldeyra Therapeutics (ALDX)")
Sales per employee in the market segment - Pharma eyes
Aldeyra Therapeutics (ALDX) is a biotech company developing drugs to treat immune-mediated diseases, with a particular focus on ophthalmic diseases (e.g., dry eye). This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform in the ophthalmology niche.
Sales per employee for the market as a whole
Aldeyra Therapeutics (ALDX) is a biopharmaceutical company developing therapies for immune-mediated diseases (primarily ocular). This is an R&D business. The company does not yet have stable commercial revenue (the recently approved Reproxalap will not generate it immediately). This metric does not yet reflect operational efficiency.
Short shares by company, segment and market as a whole
Shares shorted by company Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics is a biotech company focused on treating ocular and systemic inflammatory diseases. This chart shows bearish bets. The bears are betting on regulatory risk: the FDA previously rejected the company's application, and skeptics doubt the new data will convince the regulator.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aldeyra-Therapeutics-ALDX&v=1772640839840 "Short Shares Chart for the Company Aldeyra Therapeutics (ALDX)")
Shares shorted by market segment - Pharma eyes
Aldeyra Therapeutics is a biotech company developing drugs to treat inflammatory diseases, primarily eye diseases (dry eye syndrome). This chart shows bearish sentiment. "Shorts" here are bets that their drugs will not receive FDA approval or will lose out to competitors.
Shares shorted by the overall market
Aldeyra Therapeutics is a biotech company specializing in the treatment of inflammatory eye diseases. It's a niche but important area. This chart highlights the overall market pessimism. Biotech stocks often live in anticipation of FDA decisions. But when fear reigns supreme, even positive news can be ignored, and any negative news can be amplified.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aldeyra Therapeutics (ALDX)
Aldeyra Therapeutics (ALDX) is a biotech company focused on treating immune diseases, particularly eye diseases (dry eye syndrome). Their success depends on FDA approvals. This chart measures hype. It shows "overheated" (above 70) on approval expectations or "oversold" (below 30) on news of a regulatory rejection (which they've had before).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aldeyra-Therapeutics-ALDX&v=1772640839909 "RSI 14 indicator chart for the company's stock Aldeyra Therapeutics (ALDX)")
RSI 14 Market Segment - Pharma eyes
Aldeyra (ALDX) is a biotech company focused on treating inflammatory eye diseases (dry eye syndrome) and immune diseases. The RSI_14_Seg for "Pharma Eyes" (biotech) shows the overall sentiment. The chart helps us understand: is ALDX's volatility a reaction to its trials or is the entire sector overheated?
RSI 14 for the overall market
Aldeyra Therapeutics (ALDX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALDX (Aldeyra Therapeutics)
Aldeyra Therapeutics is a biotech company focused on treating immune-mediated eye diseases (such as dry eye). Their approach targets aldehydes. This chart shows the average 12-month analyst forecast. Their target price reflects their collective assessment of the approval chances and commercial success of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALDX-Aldeyra-Therapeutics&v=1772640840018 "A chart showing analyst consensus forecasts for the expected stock price. ALDX (Aldeyra Therapeutics)")
The difference between the consensus estimate and the actual stock price ALDX (Aldeyra Therapeutics)
Aldeyra Therapeutics is a biopharmaceutical company specializing in the treatment of immune-inflammatory diseases, primarily eye diseases (dry eye syndrome). This chart shows the difference between the market valuation and the analyst consensus forecast. It indicates whether experts believe the approval and commercial success of their drugs will be achieved.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALDX-Aldeyra-Therapeutics&v=1772640840059 "A chart showing the difference between the consensus forecast and the actual stock price. ALDX (Aldeyra Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Aldeyra Therapeutics is a biopharmaceutical company developing drugs for inflammatory eye diseases. Its success depends on FDA approval and commercialization of its R&D. This chart shows analysts' overall expectations for the ophthalmic pharmaceutical sector. It reflects whether experts believe in the potential of new ophthalmic drugs.
Analysts' consensus forecast for the overall market share price
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-inflammatory diseases, primarily ocular (such as dry eye). This chart shows overall risk appetite. For Aldeyra, whose value depends on regulatory approval, overall market optimism is important for funding, but FDA news carries far more weight than general sentiment.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aldeyra Therapeutics
Aldeyra Therapeutics is a biotech company specializing in the treatment of immune-mediated diseases, with a particular focus on ophthalmology (dry eye). This graph is an assessment of their R&D pipeline. Its dynamics are a roller coaster, reflecting their progress in clinical trials and, crucially, their dialogue and decisions with the regulator (FDA).
AKIMA Market Segment Index - Pharma eyes
Aldeyra (ALDX) is a clinical-stage biotech focused on immunology; after recent setbacks, the company is developing new drugs for the treatment of eye diseases (dry eye) and systemic inflammation. This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does this risky (R&D) model (ALDX) compare to the average pharma company?
The AKIM Index for the overall market
Aldeyra Therapeutics is a biotech company developing drugs to treat immune-mediated eye diseases (dry eye, allergic conjunctivitis). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, which is overcoming regulatory barriers, compares to overall economic trends.
